TANDEARIL
LOE ApproachingNDAORALTABLET
Approved
Dec 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TANDEARIL is an oral small-molecule tablet approved by Novartis in 1960 for an undisclosed indication. The specific mechanism of action, generic name, and therapeutic indications are not publicly documented in available records. This product represents a legacy asset from the early NDA era.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30/100), brand support and commercial headcount are likely contracting or transitioning to post-patent strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TANDEARIL currently has zero linked job openings, reflecting its LOE-approaching status and declining commercial relevance. Career opportunities on this product are severely limited and likely involve transition, exit, or legacy management responsibilities rather than growth-oriented roles.
Brand ManagerField Sales Representative
Worked on TANDEARIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.